Essential Reads: A Comprehensive Review of Brexanolone for the Treatment of Postpartum Depression
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
NPR’s 1A Live hosts an episode focusing on perinatal depression, including information on the new medication zuranolone for the treatment of postpartum depression.Â
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Although new mothers describe breastfeeding as a meaningful and fulfilling aspect of caring for their infants, breastfeeding is also a common source of stress and anxiety. A recent study suggests that difficulties with breastfeeding may [...]
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
The omega-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential components of the human diet and have a broad range of health benefits. Furthermore, they may also be beneficial [...]
About 15% of women will experience postpartum depression after the birth of a child. While most of those women will have unipolar depression, a certain number of women will have bipolar depression. At this juncture, [...]
Suicide is a leading cause of maternal mortality in the United States. According to a 2017 study from California, drug-related deaths (3.68 per 100,000 person-years) and suicides (1.42 per 100,000 person-years) accounted for nearly [...]
Post-traumatic stress disorder (PTSD) is common among women of child-bearing age. While we are increasingly attentive to screening for depressive symptoms during pregnancy and after delivery, less often do we inquire about PTSD symptoms. [...]
The US Preventive Services Task Force (USPSTF) issued recommendations that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and recommends that women at increased risk for [...]